Lataa...
Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review
OBJECTIVE: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurr...
Tallennettuna:
| Julkaisussa: | Clin Med Insights Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5989046/ https://ncbi.nlm.nih.gov/pubmed/29887734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1179554918779587 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|